Correlation Between PDS Biotechnology and Cardiff Oncology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both PDS Biotechnology and Cardiff Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PDS Biotechnology and Cardiff Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between PDS Biotechnology Corp and Cardiff Oncology, you can compare the effects of market volatilities on PDS Biotechnology and Cardiff Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PDS Biotechnology with a short position of Cardiff Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of PDS Biotechnology and Cardiff Oncology.

Diversification Opportunities for PDS Biotechnology and Cardiff Oncology

-0.23
  Correlation Coefficient

Very good diversification

The 3 months correlation between PDS and Cardiff is -0.23. Overlapping area represents the amount of risk that can be diversified away by holding PDS Biotechnology Corp and Cardiff Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardiff Oncology and PDS Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PDS Biotechnology Corp are associated (or correlated) with Cardiff Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardiff Oncology has no effect on the direction of PDS Biotechnology i.e., PDS Biotechnology and Cardiff Oncology go up and down completely randomly.

Pair Corralation between PDS Biotechnology and Cardiff Oncology

Given the investment horizon of 90 days PDS Biotechnology Corp is expected to under-perform the Cardiff Oncology. But the stock apears to be less risky and, when comparing its historical volatility, PDS Biotechnology Corp is 1.63 times less risky than Cardiff Oncology. The stock trades about -0.07 of its potential returns per unit of risk. The Cardiff Oncology is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  187.00  in Cardiff Oncology on November 3, 2024 and sell it today you would earn a total of  216.00  from holding Cardiff Oncology or generate 115.51% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

PDS Biotechnology Corp  vs.  Cardiff Oncology

 Performance 
       Timeline  
PDS Biotechnology Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days PDS Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Cardiff Oncology 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Cardiff Oncology are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent fundamental indicators, Cardiff Oncology reported solid returns over the last few months and may actually be approaching a breakup point.

PDS Biotechnology and Cardiff Oncology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with PDS Biotechnology and Cardiff Oncology

The main advantage of trading using opposite PDS Biotechnology and Cardiff Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PDS Biotechnology position performs unexpectedly, Cardiff Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiff Oncology will offset losses from the drop in Cardiff Oncology's long position.
The idea behind PDS Biotechnology Corp and Cardiff Oncology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Complementary Tools

Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing